LONDON--(BUSINESS WIRE)--A study evaluating the overall cost impact of REVLIMID (lenalidomide) use in newly-diagnosed multiple myeloma (NDMM) patients in the five largest European Union markets (EU5) determined that while drug acquisition costs were higher for lenalidomide in first-line, the additional cost was partly offset by a reduction in costs of other NDMM therapies and a reduction in cost of lenalidomide in later lines. Additionally, the study determined that lenalidomide was associated with the lowest hospitalization costs of the therapies analyzed. The study was presented at the 57th American Society of Hematology Annual Meeting.
